Disulfiram

Revision as of 21:20, 24 February 2015 by Vignesh Ponnusamy (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Disulfiram
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING
See full prescribing information for complete Boxed Warning.
  • Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge.
  • The physician should instruct relatives accordingly.

Overview

Disulfiram is an alcohol antagonist that is FDA approved for the treatment of alcoholism. There is a Black Box Warning for this drug as shown here. Common adverse reactions include dermatitis and garlic-like or metallic aftertaste.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Alcoholism
  • Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage.
  • Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic.
  • Disulfiram should never be administered until the patient has abstained from alcohol for at least 12 hours.
  • Initial Dosage Schedule
  • In the first phase of treatment, a maximum of 500 mg daily is given in a single dose for one to two weeks. Although usually taken in the morning, disulfiram may be taken on retiring by patients who experience a sedative effect. Alternatively, to minimize, or eliminate, the sedative effect, dosage may be adjusted downward.
  • Maintenance Regimen
  • The average maintenance dose is 250 mg daily (range, 125 to 500 mg), it should not exceed 500 mg daily.
  • Note: Occasionally patients, while seemingly on adequate maintenance doses of disulfiram, report that they are able to drink alcoholic beverages with impunity and without any symptomatology. All appearances to the contrary, such patients must be presumed to be disposing of their tablets in some manner without actually taking them. Until such patients have been observed reliably taking their daily disulfiram tablets (preferably crushed and well mixed with liquid), it cannot be concluded that disulfiram is ineffective.
  • Duration of Therapy
  • The daily, uninterrupted administration of disulfiram must be continued until the patient is fully recovered socially and a basis for permanent self-control is established. Depending on the individual patient, maintenance therapy may be required for months or even years.
  • Trial with Alcohol
  • During early experience with disulfiram, it was thought advisable for each patient to have at least one supervised alcohol-drug reaction. More recently, the test reaction has been largely abandoned. Furthermore, such a test reaction should never be administered to a patient over 50 years of age. A clear, detailed and convincing description of the reaction is felt to be sufficient in most cases.
  • However, where a test reaction is deemed necessary, the suggested procedure is as follows:
  • After the first one to two weeks’ therapy with 500 mg daily, a drink of 15 mL (1/2 oz) of 100 proof whiskey, or equivalent, is taken slowly. This test dose of alcoholic beverage may be repeated once only, so that the total dose does not exceed 30 mL (1 oz) of whiskey. Once a reaction develops, no more alcohol should be consumed. Such tests should be carried out only when the patient is hospitalized, or comparable supervision and facilities, including oxygen, are available.
  • Management of Disulfiram-Alcohol Reaction
  • In severe reactions, whether caused by an excessive test dose or by the patient’s unsupervised ingestion of alcohol, supportive measures to restore blood pressure and treat shock should be instituted. Other recommendations include: oxygen, carbogen (95% oxygen and 5% carbon dioxide), vitamin C intravenously in massive doses (1 g) and ephedrine sulfate. Antihistamines have also been used intravenously. Potassium levels should be monitored, particularly in patients on digitalis, since hypokalemia has been reported.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Disulfiram in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Disulfiram in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Disulfiram in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Disulfiram in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Disulfiram in pediatric patients.

Contraindications

  • Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram.
  • Disulfiram is contraindicated in the presence of severe myocardial disease or coronary occlusion, psychoses, and hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization.

Warnings

WARNING
See full prescribing information for complete Boxed Warning.
  • Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge.
  • The physician should instruct relatives accordingly.
  • The Disulfiram-Alcohol Reaction
  • Concomitant Conditions
  • Because of the possibility of an accidental disulfiram-alcohol reaction, disulfiram should be used with extreme caution in patients with any of the following conditions: diabetes mellitus, hypothyroidism, epilepsy, cerebral damage, chronic and acute nephritis, hepatic cirrhosis or insufficiency.
  • The patient must be fully informed of the disulfiram-alcohol reaction. He must be strongly cautioned against surreptitious drinking while taking the drug, and he must be fully aware of the possible consequences. He should be warned to avoid alcohol in disguised forms, i.e., in sauces, vinegars, cough mixtures, and even in aftershave lotions and back rubs. He should also be warned that reactions may occur with alcohol up to 14 days after ingesting disulfiram.

Precautions

  • Patients with a history of rubber contact dermatitis should be evaluated for hypersensitivity to thiuram derivatives before receiving disulfiram.
  • Alcoholism may accompany or be followed by dependence on narcotics or sedatives. Barbiturates and disulfiram have been administered concurrently without untoward effects; the possibility of initiating a new abuse should be considered.
  • Baseline and follow-up liver function tests (10 to 14 days) are suggested to detect any hepatic dysfunction that may result with disulfiram therapy. In addition, a complete blood count and serum chemistries, including liver function tests, should be monitored.
  • Patients taking disulfiram tablets should not be exposed to ethylene dibromide or its vapors. This precaution is based on preliminary results of animal research currently in progress that suggest a toxic interaction between inhaled ethylene dibromide and ingested disulfiram resulting in a higher incidence of tumors and mortality in rats. A correlation between this finding and humans, however, has not been demonstrated.

Adverse Reactions

Clinical Trials Experience

  • Multiple cases of hepatitis, including both cholestatic and fulminant hepatitis, as well as hepatic failure resulting in transplantation or death, have been reported with administration of disulfiram.
  • Occasional skin eruptions are, as a rule, readily controlled by concomitant administration of an antihistaminic drug.
  • In a small number of patients, a transient mild drowsiness, fatigability, impotence, headache, acneform eruptions, allergic dermatitis, or a metallic or garlic-like aftertaste may be experienced during the first two weeks of therapy. These complaints usually disappear spontaneously with the continuation of therapy, or with reduced dosage.
  • Psychotic reactions have been noted, attributable in most cases to high dosage, combined toxicity (with metronidazole or isoniazid), or to the unmasking of underlying psychoses in patients stressed by the withdrawal of alcohol.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Disulfiram in the drug label.

Drug Interactions

  • Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.
  • Disulfiram should be used with caution in those patients receiving phenytoin and its congeners, since the concomitant administration of these two drugs can lead to phenytoin intoxication. Prior to administering disulfiram to a patient on phenytoin therapy, a baseline phenytoin serum level should be obtained. Subsequent to initiation of disulfiram therapy, serum levels of phenytoin should be determined on different days for evidence of an increase or for a continuing rise in levels. Increased phenytoin levels should be treated with appropriate dosage adjustment.
  • Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status, the disulfiram should be discontinued if such signs appear.
  • In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic. Disulfiram alone in the rat’s diet did not lead to such tumors. The relevance of this finding to humans is not known at this time.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category
  • The safe use of this drug in pregnancy has not been established. Therefore, disulfiram should be used during pregnancy only when, in the judgement of the physician, the probable benefits outweigh the possible risks.


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Disulfiram in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Disulfiram during labor and delivery.

Nursing Mothers

  • It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, disulfiram should not be given to nursing mothers.

Pediatric Use

  • Safety and effectiveness in pediatric patients have not been established.

Geriatic Use

  • A determination has not been made whether controlled clinical studies of disulfiram included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Gender

There is no FDA guidance on the use of Disulfiram with respect to specific gender populations.

Race

There is no FDA guidance on the use of Disulfiram with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Disulfiram in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Disulfiram in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Disulfiram in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Disulfiram in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

  • Baseline and follow-up liver function tests (10 to 14 days) are suggested to detect any hepatic dysfunction that may result with disulfiram therapy. In addition, a complete blood count and serum chemistries, including liver function tests, should be monitored.

IV Compatibility

There is limited information regarding IV Compatibility of Disulfiram in the drug label.

Overdosage

Chronic Overdose

There is limited information regarding Chronic Overdose of Disulfiram in the drug label.

Pharmacology

Template:Px
Template:Px
Disulfiram
Systematic (IUPAC) name
1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane
Identifiers
CAS number 97-77-8
ATC code N07BB01 P03AA04 (WHO)
PubChem 3117
DrugBank DB00822
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 296.539 g/mol
SMILES eMolecules & PubChem
Synonyms 1-(diethylthiocarbamoyldisulfanyl)-N,N-diethyl-methanethioamide
Pharmacokinetic data
Bioavailability ?
Metabolism Hepatic to diethylthiocarbamate
Half life 60–120 hours
Excretion ?
Therapeutic considerations
Pregnancy cat.

C (US)

Legal status
Routes Oral, subdermal implant

Mechanism of Action

  • Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol.
  • Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage. During alcohol metabolism following disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism of the same amount of alcohol alone.
  • Accumulation of acetaldehyde in the blood produces a complex of highly unpleasant symptoms referred to hereinafter as the disulfiram-alcohol reaction. This reaction, which is proportional to the dosage of both disulfiram and alcohol, will persist as long as alcohol is being metabolized. Disulfiram does not appear to influence the rate of alcohol elimination from the body.

Structure

  • Disulfiram, USP is an alcohol antagonist drug.
  • Chemical name
  • bis(diethylthiocarbamoyl) disulfide.
  • Structural Formula
This image is provided by the National Library of Medicine.
  • Disulfiram, USP occurs as a white to off-white, odorless, and almost tasteless powder, soluble in water to the extent of about 20 mg in 100 mL, and in alcohol to the extent of about 3.8 g in 100 mL.
  • Each tablet for oral administration contains 250 mg or 500 mg disulfiram, USP. Tablets also contain colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, and stearic acid

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Disulfiram in the drug label.

Pharmacokinetics

  • Disulfiram is absorbed slowly from the gastrointestinal tract and is eliminated slowly from the body. One (or even two) weeks after a patient has taken his last dose of disulfiram, ingestion of alcohol may produce unpleasant symptoms.
  • Prolonged administration of disulfiram does not produce tolerance; the longer a patient remains on therapy, the more exquisitely sensitive he becomes to alcohol.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Disulfiram in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Disulfiram in the drug label.

How Supplied

  • Disulfiram Tablets USP
  • 250 mg:
  • White, round, unscored, biconvex tablets, debossed with “OP” over “706” on one side and plain on the other side.
  • Available in bottles of 100 tablets.
  • 500 mg:
  • White, round, scored tablets, debossed with “OP” over “707” on one side and scored on the other side.
  • Available in bottles of 100 tablets.
  • Store at 20° to 25°C (68° to 77°F).
  • Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
  • KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Storage

There is limited information regarding Disulfiram Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Disulfiram |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Disulfiram |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Disulfiram in the drug label.

Precautions with Alcohol

  • Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol.

Brand Names

Look-Alike Drug Names

There is limited information regarding Disulfiram Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "ANTABUSE- disulfiram tablet".

{{#subobject: 

 |Page Name=Disulfiram
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Disulfiram
 |Label Name=Disulfiram02.png

}}

{{#subobject: 

 |Label Page=Disulfiram
 |Label Name=Disulfiram03.png

}}

{{#subobject: 

 |Label Page=Disulfiram
 |Label Name=Disulfiram04.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Disulfiram&oldid=1073159"